Chemoprevention Study of Selenium for Non-Small Cell Lung Cancer
Untitled Document
Name of the Trial
Phase III Randomized Chemoprevention Study of Selenium in Participants With
Previously Resected Stage I Non-Small Cell Lung Cancer (ECOG-5597). See the
protocol summary.
Principal Investigators
 |
Dr. Daniel Karp
Principal Investigator |
Dr. Daniel David Karp, Eastern Cooperative Oncology Group; Dr. Omer Kucuk,
Southwest Oncology Group; Dr. Randolph Marks, North Central Cancer Treatment
Group; Dr. Michael R. Johnston, National Cancer Institute of Canada; Dr. Gerald
H. Clamon, Cancer and Leukemia Group B; Dr. Steven Belinsky, Lovelace Respiratory
Research Institute.
Why Is This Trial Important?
Lung cancer is responsible for more cancer deaths in America than breast cancer,
colon cancer, and prostate cancer combined. In its earliest stages, non-small
cell lung cancer (NSCLC) may be removed surgically with potentially curative
results. However, the incidence of a second tumor developing in patients who
have been treated surgically for early-stage NSCLC is about 20 to 30 percent.
In this study, researchers are investigating the ability of selenium to prevent
the development of secondary lung tumors in patients with surgically removed,
early-stage NSCLC. Selenium is an essential dietary mineral that has been shown
in animal studies to inhibit the growth of tumors. It is also associated with
reduced cancer incidence in some animal populations.
"Selenium may help prevent cancer through a number of different mechanisms,"
said Dr. Karp. "It is an essential component of the antioxidant enzyme glutathione peroxidase, which protects tissue from oxidative damage and may
help stimulate apoptosis (cell death). Selenium may also play an anti-inflammatory
role by blocking the 5-lipoxygenase pathway."
Who Can Join This Trial?
Researchers seek to enroll 1,960 patients 18 years of age and older who have
had stage I NSCLC completely removed by surgery. See the list
of eligibility criteria.
Where Is This Trial Taking Place?
Study sites in the United States and Canada are enrolling patients in this
trial. See the list
of study sites.
Contact Information
See the list
of study contacts or call the NCI's Cancer Information Service at 1-800-4-CANCER
(1-800-422-6237). The call is toll free and completely confidential.
Back to Top |
